Bekoz, H. Et Al. 2017. Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience. Annals of Oncology , vol.28, no.10 , 2496-2502.

Bekoz, H., Karadurmus, N., Paydas, S., Turker, A., Toptas, T., Tuglular, T. F., ... Sonmez, M.(2017). Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience. Annals of Oncology , vol.28, no.10, 2496-2502.

Bekoz, H. Et Al. "Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience," Annals of Oncology , vol.28, no.10, 2496-2502, 2017

Bekoz, H. Et Al. "Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience." Annals of Oncology , vol.28, no.10, pp.2496-2502, 2017

Bekoz, H. Et Al. (2017) . "Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience." Annals of Oncology , vol.28, no.10, pp.2496-2502.

@article{article, author={H. Bekoz Et Al. }, title={Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience}, journal={Annals of Oncology}, year=2017, pages={2496-2502} }